Biolegend, 802802, Purified anti-APP C-Terminal Fragment Antibody (Previously Covance catalog# SIG-39152), 1ml

APP functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. It is involved in cell mobility and transcription regulation through protein-protein interactions and cleaved either by alpha-secretase, beta-secretase or theta-secretase, leading to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, and the retention of corresponding membrane-anchored C-terminal fragments, C80, C83 and C99. Subsequent processing of C80 and C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 and amyloid-beta 42, major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59). Many other minor beta-amyloid peptides, beta-amyloid 1-X peptides, are found in cerebral spinal fluid (CSF) including the beta-amyloid X-15 peptides, produced from the cleavage by alpha-secretase and all terminating at Gln-686.
1ml
Verified Reactivity: Human, Mouse, Rat
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: This antibody was raised against the conserved carboxyl-terminal 20 residues of APP (residues 676-695 of APP695).
Formulation: Phosphate-buffered solution (no preservatives or carrier proteins).
Preparation: The antibody was purified by affinity chromatography.
Concentration: 1 mg/ml
Storage & Handling: This antibody should be handled aseptically as it is free of preservatives such as Sodium Azide. Store this antibody undiluted between 2°C and 8°C. Please note the storage condition for this antibody has been changed from -20°C to between 2°C and 8°C. You can also check the vial label or CoA to find the proper storage conditions.
Application: WB - Quality testedICC, IP - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by Western blotting. For Western blotting, the suggested use of this reagent is 1.0 - 2.0 µg per ml. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: This antibody is effective in immunoblotting (WB), immunocytochemistry (ICC), and immunoprecipitation (IP).
Application References(PubMed link indicates BioLegend citation): Lee MH, et al. 2010. Cell Death Dis. e110. Jiang Y, et al. 2010. Proc. Natl. Acad. Sci. USA. 107(4):1630-5. (WB, ICC) PubMed Laudon H, et al. 2004. J. Biol. Chem. 279(23):23925-32. (IP) Grbovic OM, et al. 2003. J. Biol. Chem. 278(33):31261-8. (IP) Mathews PM, et al. 2002. J. Biol. Chem. 277(39):36415-24. (WB)
Product Citations: de Coninck D, et al. 2018. Biophys J. 114:1128. PubMed Sogorb-Esteve A, et al. 2018. Mol Neurobiol. 55:5047. PubMed Ruan X, et al. 2023. Nat Commun. 14:3275. PubMed Shamji MH, et al. 2015. J Allergy Clin Immunol. 913:135. PubMed Lin T, et al. 2022. Glycobiology. 32:506. PubMed Chae CW, et al. 2020. Br J Pharmacol. 177:3828. PubMed Arber C, et al. 2019. Brain Commun. 1:fcz024. PubMed Lingel A, et al. 2020. J Biol Chem. 295:17114. PubMed Miranda AM, et al. 2018. Nat Commun. 9:291. PubMed Lingel A, et al. 2020. J Biol Chem. 295:17114. PubMed Reichenbach N, et al. 2018. J Exp Med. 215:1649. PubMed García-Ayllón MS, et al. 2017. Sci Rep. 7:2477. PubMed Jiwaji Z, et al. 2022. Nat Commun. 13:135. PubMed Lundgren JL, et al. 2020. BMC Neurosci. 21:06. PubMed Reichenbach N, et al. 2019. EMBO Mol Med. 11:. PubMed Koh HS, et al. 2021. Int J Mol Sci. 22:. PubMed Kotfis K, et al. 2020. British Journal of Pharmacology. 49(1):66-72. PubMed Liu YC, et al. 2020. Mol Ther. . PubMed Paschkowsky S, et al. 2016. J Biol Chem. 291: 21903 - 21912.. PubMed Jiang Y, et al. 2010. Proc Natl Acad Sci U S A. 107:1630-1635. PubMed Arber C, et al. 2021. Cell Reports. 34(2):108615. PubMed Bourdenx M, et al. 2021. Cell. 184(10):2696-2714.e25. PubMed Jean-Louis T, et al. 2018. Neurobiol Aging. 62:130. PubMed Corbett G, et al. 2015. Proc Natl Acad Sci U S A. 112: 8445 - 8450. PubMed Arber C, et al. 2020. Mol Psychiatry. 25:2919. PubMed Hung C, et al. 2021. Cell Reports. 35(11):109259. PubMed Hung COY et al. 2018. Cell reports. 25(13):3647-3660 . PubMed Zhuravleva V, et al. 2021. Cell Death Dis. 12:1137. PubMed Williamson RL, et al. 2017. J Biol Chem. 292:19873. PubMed
RRID: AB_2715853 (BioLegend Cat. No. 802803) AB_2564648 (BioLegend Cat. No. 802801) AB_2564647 (BioLegend Cat. No. 802802)
Structure: Expected MW: APP= 100 kD; alphaCTF & betaCTF= 10 kD
Biology Area: Cell Biology, Neurodegeneration, Neuroscience, Protein Misfolding and Aggregation
Molecular Family: APP/β-Amyloid
Gene ID: 351
UniProt: View information about APP C-Terminal Fragment on UniProt.org
Clone: C1/6.1
Regulatory Status: RUO
Other Names: AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, Amyloid beta A4 protein, preA4, protease nexin-II, peptidase nexin-II, beta-amyloid peptide, alzheimer disease amyloid protein, cerebral vascular amyloid peptide, APP, Amyloid Precursor Protein
Previously: Covance Catalog# SIG-39152
Isotype: Mouse IgG1